For IPO Boutique's "scale of 1 to 5" BUY rating on OncoMed Pharmaceuticals, and our comprehensive analysis, click the "Buy Market Research" link.
About OncoMed Pharmaceuticals (adapted from OncoMed Pharmaceuticals prospectus): OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. Their approach has been to target CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..
Share this IPO Profile:
IPO Boutique aggregates information on public companies and private companies, such as "OMED" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.